Monte Rosa Therapeutics, Inc. (GLUE) Cash Flow Statement
Monte Rosa Therapeutics, Inc. (GLUE) generated -$24.1M of operating cash flow over the twelve months to 2026-06-30, spent $8.0M on capital expenditure and had free cash flow of -$32.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GLUEMonte Rosa Therapeutics, Inc.Follow GLUE — free
—
Price chart with a free account
- Market cap
- 924.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | 42.0 | -22.8 | -24.1 | |
| Capital expenditure | 4.0 | 4.7 | -8.0 | |
| Free cash flow | 38.0 | -27.5 | -32.1 | |
| Dividends paid | 0.0 | 0.0 | — | |
| Stock-based compensation | 18.1 | 18.9 | — |
USD millions · SEC XBRL
Monte Rosa Therapeutics, Inc. — questions
- What is Monte Rosa Therapeutics, Inc.'s operating cash flow?
- -$24.1M over the twelve months to 2026-06-30.
- How much does Monte Rosa Therapeutics, Inc. spend on capital expenditure?
- $8.0M over the twelve months to 2026-06-30.
- What is Monte Rosa Therapeutics, Inc.'s free cash flow?
- -$32.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Monte Rosa Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.